课题基金 / 基金详情

Pharmacology and Bioengineering of New Treatment of ITP

Pharmacology and Bioengineering of New Treatment of ITP
ITP新疗法的药理学和生物工程
批准号:
7848331
负责人:
Joseph P Balthasar
金额:
$35.32万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-11 至 2011-11-30

项目摘要

项目成果

Joseph P Balthasar的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):免疫性血小板减少性紫癜(ITP)是一种常见的自身免疫性疾病,在美国每年约有50,000例新发病例。大约25-30%的慢性ITP患者对标准治疗(皮质类固醇免疫抑制和脾切除术)难治,并且具有致死性出血的高风险。目前没有可行的替代疗法,并且由于缺乏合适的疾病动物模型,新疗法的开发进展缓慢。然而,在该项目上进行的工作已经导致了新的、可重复的、定量的ITP大鼠和小鼠模型的开发,现在可以对新的治疗策略进行系统评价。已经进行了实验来探讨大剂量静脉注射免疫球蛋白(IVIG)治疗ITP的作用机制。这项工作表明,IVIG提供的大部分益处来自FcRn的竞争性抑制,其保护IgG免于降解。此外,我们启动了三种新的ITP治疗策略的开发和评估(即,应用特异性FcRn抑制剂以增加致病性抗血小板抗体的消除,用抗原特异性体外生物反应器去除抗血小板抗体,以及通过使用抗体包被的脂质体作为“诱饵颗粒”来抑制血小板破坏)。在最初的供资期间,每个具体目标都产生了非常有希望的结果。这种竞争性更新将建立在这些结果的基础上,测试IVIG在ITP的脾切除小鼠模型中的作用机制(目标#1),优化抗体包被的脂质体的制剂以增强药代动力学和药效学特性,并测试与抗体包被的脂质体在ITP中的作用机制相关的假设(目标#2)。目标#3将开发和评价一种新的ITP免疫复合物疗法,目标#4将优化中空纤维生物反应器的构建,以有效和选择性地体外清除致病性抗血小板抗体。从拟议的研究中收集的发现有望导致难治性ITP的新治疗方法的开发。此外,在该项目上进行的工作可以为设计治疗所有自身免疫性疾病的有效策略提供见解,这些疾病共同影响1400万至2200万美国人。
英文摘要
DESCRIPTION (provided by applicant): Immune thrombocytopenic purpura (ITP) is a common autoimmune disease that is associated with ~50,000 new cases each year in the United States. Approximately 25-30% of chronic ITP patients are refractory to standard therapy (corticosteroid immunosuppression and splenectomy) and are at high risk for fatal hemorrhage. No feasible alternative therapies are presently available, and progress toward the development of new treatments had been slowed be the lack of suitable animal models of the disease. However, work conducted on this project has led to the development of new, reproducible, quantitative rat and mouse models of ITP, which now allow the systematic evaluation of new treatment strategies. Experiments have been conducted to probe the mechanisms responsible for the effects of high-dose intravenous immunoglobulin (IVIG) therapy of ITP. This work demonstrated that much of the benefit provided by IVIG results from the competitive inhibition of the FcRn, which protects IgG from degradation. Additionally, we initiated the development and evaluation of three new therapeutic strategies for ITP (i.e., application of specific FcRn-inhibitors to increase the elimination of pathogenic antiplatelet antibodies, removal of antiplatelet antibodies with an antigen-specific extracorporeal bioreactor, and inhibition of platelet destruction through the use of antibody-coated liposomes as "decoy particles"). Extremely promising results were generated from each specific aim during the initial funding period. This competing renewal will build upon these results, testing proposed mechanisms of IVIG action in a splenectomized-mouse model of ITP (Aim #1), optimizing the formulation of antibody-coated liposomes for enhanced pharmacokinetic and pharmacodynamic properties, and testing hypotheses related to the mechanisms of effect of antibody-coated liposomes in ITP (Aim #2). Aim #3 will develop and evaluate a new immune complex therapy for ITP, and Aim #4 will optimize the construction of hollow fiber bioreactors for efficient and selective extracorporeal removal of pathogenic, antiplatelet antibodies. Findings gathered from the proposed studies are expected to lead toward the development of new treatments for refractory ITP. Additionally, work conducted on this project may offer insight in the design of effective strategies for the treatment of all autoimmune conditions, which collectively affect 14-22 million Americans.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
Mechanisms of IVIG action in immune thrombocytopenic purpura.
IVIG 在免疫性血小板减少性紫癜中的作用机制。
DOI: --
发表时间: 2004
期刊: Clinical laboratory.
影响因子: --
作者: [Hansen,RyanJ, Balthasar,JosephP]
通讯作者: Balthasar,JosephP
DOI: 10.1182/blood.v100.6.2087.h81802002087_2087_2093
发表时间: 2002-09-15
期刊: BLOOD
影响因子: 20.3
作者: [Hansen, RJ, Balthasar, JP]
通讯作者: Balthasar, JP
Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia.
高剂量单克隆抗体治疗对免疫性血小板减少症大鼠模型的药代动力学和药效学影响。
DOI: 10.1208/aapsj070487
发表时间: 2005
期刊: The AAPS journal
影响因子: --
作者: [Jin,Feng, Tayab,ZiaR, Balthasar,JosephP]
通讯作者: Balthasar,JosephP
Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura.
抗糖蛋白 IIb/IIIa 单克隆抗体 (7E3) 在大鼠体内的药代动力学、药效学和血小板结合:免疫性血小板减少性紫癜的定量大鼠模型。
DOI: --
发表时间: 2001
期刊: The Journal of pharmacology and experimental therapeutics
影响因子: --
作者: [Hansen,RJ, Balthasar,JP]
通讯作者: Balthasar,JP
共 7 条
    Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia
    Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
    Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
    Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
    海外基金